Phase 4
Completed N=215
Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis
Source: ClinicalTrials.gov NCT01159769 ↗Enrolled (actual)
215
Serious AEs
0.9%
Results posted
Apr 2012
Primary outcomePrimary: Overall Patient Satisfaction — 70.1 Percentage of Participants
Summary
The purpose of this study is to evaluate patient perceptions of olopatadine 0.2% dosed once daily in patients previously treated with twice-daily, topical, ocular, anti-allergy medications.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Patient Satisfaction |
89.3 | — |
| PRIMARY Overall Patient Satisfaction |
89.3 | — |
Eligibility Criteria
Inclusion Criteria
- 12 years of age or older.
- History (within the past 24 months) of allergic conjunctivitis.
- Active signs and symptoms of ocular allergies.
- Ocular health within normal limits, as determined by the investigator or subinvestigator.
- Willing to avoid contact lens wear each study visit immediately prior to study medication instillation and for 10 minutes after instillation of study drug.
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria
- Contraindications or hypersensitivity to study medication or its components.
- One sighted eye or not correctable to 0.6 logMAR or better in both eyes at the screening visit.
- Known history of recurrent corneal erosion syndrome.
- Ocular trauma or surgical intervention within 6 months prior to Visit 1.
- Participation in any other investigational study within 30 days before Visit 1.
- Pregnant or nursing.
- Other protocol-defined exclusion criteria may apply.
Data sourced from ClinicalTrials.gov (NCT01159769). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.